Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative Allo-SCT with Fludarabine, Cyclophosphamide, and ATG
NCT00006379Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jun 2000
- Primary completion
- Jan 2004
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 6 more, sponsored by Case Comprehensive Cancer Center. Primary endpoint: Evaluation of Donor Engraftment at 28 days. Started Jun 2000; status: completed.
02
Drugs
fludarabine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00006379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006379.